Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer(†)

Por Falchook, G. S., Moulder, S. L., Wheler, J. J., Jiang, Y., Bastida, C. C., Kurzrock, R.
Publicado em 2013

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

Por Falchook, G.S., Trent, J.C., Heinrich, M.C, Beadling, C., Patterson, J., Bastida, C.C., Blackman, S.C., Kurzrock, R.
Publicado em 2013